- Published on
KembaraXtra- Medicine – Adult-Onset Still Disease
Adult-onset Still disease (AOSD) is a rare systemic inflammatory disorder characterized by episodes of high-spiking fever, an evanescent rash, and arthralgias/arthritis, often accompanied by lymphadenopathy, hepatosplenomegaly, and markedly elevated serum ferritin. Many patients report a prodromal sore throat, sometimes preceding systemic symptoms. The daily (quotidian) fever pattern is a striking feature, and inflammatory arthritis can become progressive and destructive over time, leading to joint damage and disability in a subset of patients.
AOSD has several synonyms, including Still disease, systemic juvenile idiopathic arthritis (systemic JIA), and Wissler (Wissler-Fanconi) syndrome. The ICD-10-CM code is M06.1. Because it is uncommon, definitive epidemiologic data are limited, but prevalence has been reported between 1 and 34 per 1,000,000, with incidence around 0.1 to 0.4 per 100,000. A bimodal age distribution is described, with peaks around 15–25 and 36–46 years, and there is no consistent gender predisposition.
Infectious triggers are suspected in genetically susceptible individuals, as onset or relapse may follow a viral-like prodrome with pharyngitis, malaise, fever, and rash, although no single organism has been consistently implicated. Studies suggest a genetic component, with some associations reported between AOSD and certain HLA types (including class II DRB115 and DRB112 for susceptibility, and class I B35 with self-limited disease, DR2/DR5 with more chronic disease), though findings have not been consistently verified across populations.
Clinically, the “cardinal” triad of AOSD is fever, arthralgias/arthritis, and rash, and it occurs in most patients. Fever typically follows a quotidian pattern with spikes often occurring in the late afternoon or evening, frequently exceeding 102°F (38.9°C) and lasting a few hours before returning to normal. A “double quotidian” pattern with a second early-morning spike occurs in some cases. The classic rash is a salmon-pink, nonpruritic, maculopapular eruption most often involving the trunk and proximal extremities. The rash may appear with fever and fade when afebrile, which can make it easy to miss; Koebner phenomenon can occur. Arthralgias and myalgias are very common, and inflammatory arthritis often presents as symmetric polyarthritis affecting larger joints, with up to half of patients developing progressive destructive arthritis. Other manifestations may include sore throat, lymphadenopathy, hepatosplenomegaly, and serositis. Cardiac involvement such as pericarditis can occur and, in severe cases, can progress to tamponade, warranting prompt recognition and treatment.
The pathogenesis is not fully defined, but the disease appears driven by innate immune dysregulation and abnormal macrophage activation. Elevated proinflammatory cytokines are commonly described, including IL-1, IL-6, IL-18, TNF-α, interferon-γ, and others. More recently, increased circulating markers related to neutrophil extracellular traps (NETs) have been observed in active disease, with reductions after treatment, though the clinical implications continue to be studied.
There is no single diagnostic test that is pathognomonic for AOSD. Diagnosis is clinical and laboratory-based and is fundamentally a diagnosis of exclusion, requiring evaluation for infectious, neoplastic, and other inflammatory causes of fever and systemic illness. Laboratory abnormalities often include neutrophilic leukocytosis (commonly WBC >12 with >80% PMNs), very elevated inflammatory markers (often ESR >50 and CRP markedly elevated), normocytic anemia, thrombocytosis, hypoalbuminemia, and mild transaminitis. Creatine kinase (CPK) is typically normal even when myalgias are prominent. Hyperferritinemia is a particularly suggestive feature, and ferritin levels can exceed five times the upper limit of normal. Autoantibodies typical of other rheumatologic diseases are usually absent, with negative rheumatoid factor and negative ANA supporting (but not confirming) the diagnosis.
Imaging can support assessment of systemic involvement and complications. Plain radiographs may show early nonspecific changes such as soft-tissue swelling, effusions, or periarticular osteopenia, while later disease can demonstrate destructive arthropathy—classically in the wrists with joint-space narrowing and eventual ankylosis, and in hips with progressive joint destruction. CT or MRI may demonstrate lymphadenopathy, hepatosplenomegaly, and early bony or soft-tissue findings. FDG PET/CT may show increased uptake in spleen, bone marrow, and reactive lymph nodes, though these findings are not specific and must be interpreted in context.
Multiple classification/diagnostic criteria sets exist. The Yamaguchi criteria are widely used because they are sensitive and practical. The Fautrel criteria are more specific but require measurement of glycosylated ferritin, which is not routinely available in many settings. Regardless of criteria, careful exclusion of mimics is essential.
Prognosis is often favorable overall, with reported 5-year survival around 90%–95%, but many patients require long-term treatment to control inflammation and prevent relapse or progressive joint damage. Clinical course typically falls into one of three patterns: a self-limited/monophasic course with remission within a year, an intermittent/relapsing course with recurrent flares separated by remission, or a chronic/progressive course dominated by persistent arthritis and erosive destruction. Features associated with progression to chronic articular disease include polyarthritis, large-joint involvement, and very high ferritin levels at presentation.
Treatment depends on severity and organ involvement. Mild disease may respond to full-dose NSAIDs alone, though sustained control occurs in a minority. Most patients require systemic glucocorticoids, particularly when systemic symptoms are prominent or there is significant organ involvement. For steroid-sparing and control of arthritis, methotrexate is commonly used. Biologic therapy is frequently effective, especially for refractory disease or patients who cannot taper steroids. IL-1 blockade (such as anakinra or canakinumab) is often highly effective for systemic symptoms and inflammation. IL-6 inhibitors (such as tocilizumab or sarilumab) and TNF inhibitors (such as etanercept or infliximab) are also used, sometimes in combination with methotrexate. Response is typically reassessed after 2–3 months, and nonresponders are often switched to a biologic with a different mechanism. After prolonged remission, cautious tapering may be attempted. In severe or refractory cases, other therapies (including IVIG, and less commonly agents like rituximab or abatacept) have been reported with limited evidence.
A critical complication to recognize is macrophage activation syndrome (MAS), also referred to as reactive hemophagocytic lymphohistiocytosis. It occurs in a notable minority of AOSD patients and can be life-threatening, with substantial mortality. MAS can resemble a severe AOSD flare, but clues that raise suspicion include cytopenias (leukopenia and thrombocytopenia), hypofibrinogenemia, hypertriglyceridemia, and sometimes a paradoxical normalization of ESR despite clinical worsening. Bone marrow aspiration demonstrating hemophagocytosis is considered the diagnostic gold standard. Initial management commonly includes pulse-dose corticosteroids, IVIG, and cytokine-directed biologic therapy (often IL-1 or IL-6 blockade), alongside intensive supportive care.
0 Comments
